AVXL Anavex Life Sciences Corp.

4.13
-0.03  -1%
Previous Close 4.16
Open 4.17
Price To book 7.38
Market Cap 174170732
Shares 42,172,090
Volume 210,032
Short Ratio 18.26
Av. Daily Volume 322,957

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 planned for 2017.
ANAVEX 2-73
Rett syndrome
Phase 2a 12-month data released December 8, 2016. Trial is ongoing. Additional Phase 2/3 trial planned for 2017.
ANAVEX 2-73
Mild to moderate Alzheimer’s disease